Phase I Study of Vandetanib During and After Radiotherapy in Children With Diffuse Intrinsic Pontine Glioma

PURPOSE: To evaluate the safety, maximum-tolerated dose, pharmacokinetics, and pharmacodynamics of vandetanib, an oral vascular endothelial growth factor receptor 2 (VEGFR2) and epidermal growth factor receptor inhibitor, administered once daily during and after radiotherapy in children with newly d...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Broniscer, Alberto, Baker, Justin N., Tagen, Michael, Onar-Thomas, Arzu, Gilbertson, Richard J., Davidoff, Andrew M., Panandiker, Atmaram Pai, Leung, Wing, Chin, Thomas K., Stewart, Clinton F., Kocak, Mehmet, Rowland, Christopher, Merchant, Thomas E., Kaste, Sue C., Gajjar, Amar
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2010
Предметы:
Original Reports
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3020706/
https://ncbi.nlm.nih.gov/pubmed/20921456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.3545
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы